Racial Disparities in Genetic Detection Rates for Inherited Retinal Diseases Academic Background Inherited retinal diseases (IRDs) are a group of degenerative retinal disorders caused by genetic mutations, which can lead to vision loss or even blindness. With advances in gene discovery and next-generation DNA sequencing, an increasing number of pat...
Academic Background and Problem Statement Fibroblast growth factor receptor inhibitors (FGFRi) are a class of targeted drugs used to treat intrahepatic cholangiocarcinoma (iCCA). Although FGFRi has shown significant efficacy in treating iCCA, the potential complications associated with their long-term use have not been fully studied. In particular,...
Primary Open-Angle Glaucoma Polygenic Risk Score and Risk of Disease Onset: A Post Hoc Analysis Academic Background Primary open-angle glaucoma (POAG) is the most common form of glaucoma, often associated with elevated intraocular pressure (IOP). It is an irreversible optic neuropathy that, if untreated, can lead to vision loss. While IOP-lowering ...
Extrinsic Tenase Complexes in Human Saliva Trigger Coagulation in Patients with Severe Hemophilia A Background Introduction Hemophilia A is a hereditary bleeding disorder caused by a deficiency or defect in clotting factor VIII (FVIII), inherited in an X-linked recessive pattern. Patients with severe hemophilia A often experience recurrent joint bl...
Background Introduction Chemotherapy has long been a cornerstone of cancer treatment but is accompanied by significant side effects. Among cancer patients receiving platinum-based chemotherapy drugs (e.g., cisplatin), the incidence of thromboembolic events significantly increases, including pulmonary embolism, cerebrovascular incidents, angina, and...
The Impact of Soluble B-Cell Maturation Antigen (sBCMA) on Multiple Myeloma Therapy: Interpreting the Latest Research Findings In recent years, cell-based immunotherapies have demonstrated enormous promise in the treatment of multiple myeloma (MM). Among these, BCMA-targeting T-cell engagers (TCEs) and chimeric antigen receptor (CAR) T-cell therapi...